Aduro Biotech ( ADRO ), an immunotherapy technologies bio company, said Tuesday the first patient has been dosed in the phase 1b dose escalation and dose expansion clinical trial designed to evaluate the safety and efficacy of ADU-S100, a novel Sting pathway activator, in combination with PDR001, Novartis' ( NVS ) investigational PD-1 checkpoint inhibitor, for the treatment of advanced/metastatic solid tumors or lymphomas.
The trial, which is being conducted in collaboration with Aduro's partner, Novartis, is expected to enroll approximately 175 patients at sites located in the United States, Europe, Canada, Australia and Japan.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
